AMPHASTAR PHARMACEUTICALS IN (AMPH) Stock News
NASDAQ:AMPH - Nasdaq - US03209R1032 - Common Stock - Currency: USD
AMPH Latest News, Press Releases and Analysis
Investors should take notice of NASDAQ:AMPH—it offers a great deal for the fundamentals it presents.
AMPHASTAR PHARMACEUTICALS IN has caught the attention as a great value stock. NASDAQ:AMPH excels in profitability, solvency, and liquidity, all while being very reasonably priced.
Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris.
Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Beats Revenue for Q2 2024
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amphastar Pharma (NASDAQ:AMPH) just reported results for the second quarter of ...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts
These 2 small cap healthcare stocks could boom on a new sector breakout, Wall Street analysts see up to double-digit upside in each
BetterInvesting™ Magazine Update on Amphastar Pharmaceuticals Inc. and Medtronic PLC
/PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Amphastar Pharmaceuticals Inc. (NASDAQ:...
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amphastar Pharma (NASDAQ:AMPH) just reported results for the first quarter of 2...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic competition.
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024